Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.31 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651656 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL6654969 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL9149315 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL2152710 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL6650342 | 1.00 | SPHK1 (0.39) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL5100924 | 0.98 | SPHK1 (0.37) | SPHK1SPHK2USP2HTTHSD17B10 | |
| SCHEMBL19170 | 0.90 | — | — | |
| SCHEMBL31086433 | 0.87 | SPHK1 (0.44) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL10119365 | 0.87 | SPHK1 (0.44) | SPHK1SPHK2USP2HTTPRKD3 | |
| SCHEMBL6178532 | 0.86 | SPHK1 (0.42) | SPHK1SPHK2USP2HTTPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023189817-A1 | ONIUM SALT, ONIUM SALT COMPOSITION, LIQUID COMPOSITION CONTAINING ONIUM SALT AND POLYSACCHARIDE AND PRODUCTION METHOD THEREOF, AND METHOD FOR RECOVERING POLYSACCHARIDE | 広栄化学株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20210353555-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3377110-B1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | ABBVIE DEUTSCHLAND (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-20180325833-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-15 | — | — | US | disclosed |
| EP-3377110-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-09-26 | — | — | EP | disclosed |
| EP-1913070-B1 | STABILISER COMPOSITIONS BASED ON NITROGEN COMPOUNDS FOR STABILISING HALOGENATED POLYMERS | BAERLOCHER GMBH (DE) | 2011-07-06 | — | — | EP | disclosed |
| EP-1913067-B1 | STABILIZER COMPOSITIONS BASED ON GUANIDINE OR MELAMINE COMPOUNDS TO STABILIZE HALOGEN-CONTAINING POLYMERS | BAERLOCHER GMBH (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090048374-A1 | STABILIZER COMPOSITIONS FOR HALOGENATED POLYMERS WITH IMPROVED INITIAL COLOR AND IMPROVED COLOR MAINTENANCE | BAERLOCHER GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| EP-1996649-A1 | STABILIZER COMPOSITIONS FOR HALOGENATED POLYMERS WITH IMPROVED INITIAL COLOR AND IMPROVED COLOR MAINTENANCE | Baerlocher GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
| EP-0623608-B1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-6217793-B1 | Acetylene compound, liquid crystal composition and liquid crystal element | MITSUI CHEMICALS, INC. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0632031-B1 | CONDENSED BENZOXA RING COMPOUND, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0962445-A1 | Acetylene compound, liquid crystal composition and liquid crystal element | Mitsui Chemicals, Inc. (JP) | 1999-12-08 | — | — | EP | disclosed |
| EP-0546177-B1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5574061-A | ANTILIPEMIC AGENT, ANTIATHEROSCLEROSIS, ACAT INHIBITOR | TEIJIN LIMITED (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5496853-A | FOR TREATING HYPERCHOLESTEROLEMIA | TEIJIN LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0632031-A1 | CONDENSED BENZOXA RING COMPOUND, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0623608-A1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325833-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | CLTA, ACMSD, ALKBH3 | SPHK1 1728/4885SPHK2 2030/4885USP2 1243/4885 |
| US-20210353555-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | CLTA, ACMSD, ALKBH3 | SPHK1 1728/4885SPHK2 2030/4885USP2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.